Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Reduced by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 14,202 shares of the biopharmaceutical company's stock after selling 1,514 shares during the quarter. UNIVEST FINANCIAL Corp's holdings in Regeneron Pharmaceuticals were worth $10,116,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Amundi raised its position in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the period. Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after buying an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $127,489,000. Thrivent Financial for Lutherans lifted its position in Regeneron Pharmaceuticals by 1,272.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock worth $89,179,000 after acquiring an additional 116,074 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock worth $97,338,000 after acquiring an additional 102,198 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Finally, BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $1.53 during trading on Friday, hitting $637.36. 805,912 shares of the stock were exchanged, compared to its average volume of 673,409. Regeneron Pharmaceuticals, Inc. has a 12 month low of $629.02 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market cap of $69.68 billion, a PE ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27. The stock's fifty day moving average is $683.88 and its 200 day moving average is $800.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.